Tandem Diabetes Care to Announce Second Quarter 2022 Financial Results on August 3, 2022

Rhea-AI Summary

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) is set to release its second quarter 2022 results on August 3, 2022, after market close. A conference call will follow at 4:30 PM ET to discuss financial and operating results. The event will be accessible via webcast on the company's Investor Center website, with an archive available for 30 days post-event. Tandem is dedicated to enhancing the lives of those living with diabetes through innovative insulin delivery solutions, such as the t:slim X2 insulin pump.

Positive

• Scheduled release of Q2 2022 results may indicate transparency and shareholder communication.
• Ongoing innovation in diabetes technology, highlighted by the t:slim X2 insulin pump.

Negative

• None.

SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2022 results after the financial markets close on Wednesday, August 3, 2022. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2022 financial and operating results.

A live webcast of the call will be available on Tandem Diabetes Care’s Investor Center website located at http://investor.tandemdiabetes.com in the “Events & Presentations” section. To access the call by phone, please use this link (Registration Link) and you will be provided with dial-in details, including a personal pin.

An archive of the webcast will be available for 30 days following the event on Tandem Diabetes Care’s Investor Center website located at http://investor.tandemdiabetes.com in the “Events & Presentations” section.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc., a global insulin delivery and diabetes technology company based in San Diego, California, creates new possibilities for people living with diabetes, their loved ones, and healthcare providers through a positively different experience. The Company’s human-centered approach to design, development, and support delivers innovative products and services for people who use insulin. Tandem manufactures and sells the t:slim X2 insulin pump with Control-IQ technology. For more information, visit tandemdiabetes.com.

Tandem Diabetes Care is a registered trademark and t:slim X2 is a trademark of Tandem Diabetes Care, Inc.

Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2, and $TNDM.
Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.
Follow Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/tandemdiabetes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220712005854/en/

Media Contact:

Steve Sabicer

714-907-6264

ssabicer@thesabicergroup.com

Investor Contact:

Susan Morrison

858-366-6900

IR@tandemdiabetes.com

Source: Tandem Diabetes Care, Inc.

FAQ

When will Tandem Diabetes Care release its Q2 2022 financial results?

Tandem Diabetes Care will release its Q2 2022 financial results on August 3, 2022, after market close.

What time is the conference call for Tandem Diabetes Care's Q2 2022 results?

The conference call will take place at 4:30 PM Eastern Time on August 3, 2022.

Where can I access Tandem Diabetes Care's Q2 2022 results webcast?

The webcast can be accessed on Tandem Diabetes Care's Investor Center website in the 'Events & Presentations' section.

What product does Tandem Diabetes Care focus on for diabetes management?

Tandem Diabetes Care focuses on the t:slim X2 insulin pump with Control-IQ technology for diabetes management.